Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Xijing Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01372852
First received: June 11, 2011
Last updated: June 13, 2011
Last verified: May 2010
  Purpose

The objective of present study were to compare plasma adiponectin isoform status, their bioactivities newly diagnosed Chinese with healthy volunteer.


Condition
Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population

Resource links provided by NLM:


Further study details as provided by Xijing Hospital:

Primary Outcome Measures:
  • plasma adiponectin concentration, isoform distribution and activity. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

blood,abdominal fat tissue


Estimated Enrollment: 300
Study Start Date: May 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
T2DM patients
newly diagnosed T2DM patients and untreated with any drugs.
Non-diabetic Control Group

Detailed Description:

Adiponectin, circulates as trimer, hexamer and high molecular weight form (HMW) in human blood, is a promising biomarker for indication diabetes and cardiovascular disease. Both adiponectin complexes concentration and their bioactivities are decreased in pathological state. Disulfide-bond A oxidoreductase-like protein (DsbA-L) is a key regulator for adiponectin biosynthesis and its expression level is down-regulated in obese mice and humans. However, the alteration of circulating adiponectin multimers distribution, their bioactivities and adiponectin regulator, DsbA-L level, in newly diagnosed Chinese type 2 diabetes patients are unknown. The objective of present study were to compare plasma adiponectin isoform status, their bioactivities and DsbA-L concentration in newly diagnosed Chinese with healthy volunteer.

  Eligibility

Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

This study enrolls a group of 30-70years patients from primary care clinic who have diabetes history within 12 months and without taking any treatment.

Criteria

Inclusion Criteria:

  • Having a diabetic history within 12 months
  • BMI smaller than 30kg/m2

Exclusion Criteria:

  • Having any kinds of treatment affecting glucose
  • pregnant
  • uncontrolled hypertension, active cardiac disease, or other major liver, kidney disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372852

Contacts
Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com

Locations
China, Shaanxi
Xijing Hospital Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Ling Tao, MD,PhD    +86-15002955798    lingtao2006@gmail.com   
Sponsors and Collaborators
Xijing Hospital
Investigators
Principal Investigator: Ling Tao, M.D Ph.D Department of Cardiology of Xijing Hospital, Fourth Military Medical University
  More Information

No publications provided

Responsible Party: Ling Tao, Department of Cardiology of Xijing Hospital; Fourth Military Medical University
ClinicalTrials.gov Identifier: NCT01372852     History of Changes
Other Study ID Numbers: xjyy110501
Study First Received: June 11, 2011
Last Updated: June 13, 2011
Health Authority: China: Food and Drug Administration

Keywords provided by Xijing Hospital:
Diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on April 22, 2014